The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers
Complementary business models are the reason for the acquisition
Drug formulations and biologics make impressive gains
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Subscribe To Our Newsletter & Stay Updated
